A Feasibility Study To Determine T-cell Responses To Neoantigens Following Treatment With Ipilimumab In Men With Metastatic Castration-Resistant Prostate Carcinoma

Trial Profile

A Feasibility Study To Determine T-cell Responses To Neoantigens Following Treatment With Ipilimumab In Men With Metastatic Castration-Resistant Prostate Carcinoma

Active, no longer recruiting
Phase of Trial: Phase 0

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jan 2018 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
    • 05 Jan 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
    • 05 Jan 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top